To compare the effects of initiating insulin as a fourth-line antidiabetic therapy with the effects of enhancing oral antidiabetic drug (OAD) therapy in patients with type 2 diabetes mellitus (T2DM) with triple OAD therapy failure. T2DM with/without PDRCs, fourth-line insulin therapy was associated with greater risks of the composite cardiovascular outcome (HR 1.23, 95% CI 1.03-1.46), heart failure (HR 1.59, 95% CI 1.12-2.25), ischaemic heart disease (HR 1.37, 95% CI 1.09-1.73), PVD (HR 1.17, 95% CI 1.00-1.36), hypoglycaemia (HR 1.49, 95% CI 1.20-1.85) and all-cause mortality (HR 1.48, 95% CI 1.01-2.17), but adjustment for hypoglycaemia significantly attenuated the risk of heart failure (HR 1.34, 95% CI 0.92-1.94), PVD (HR 1.15, 95% CI 0.98-1.34) and all-cause mortality (HR 1.30, 95% CI 0.84-1.99).
| INTRODUCTION
Early insulin initiation is suggested to preserve β-cell function, [1] [2] [3] but in real-world clinical practice insulin is still commonly prescribed at a later stage of an antidiabetic treatment course because of clinical inertia. 4 Most patients with type 2 diabetes mellitus (T2DM) generally do not begin insulin therapy until they have experienced poor glycaemic control using three oral antidiabetic drugs (OADs). 5 Insulin initiation is often delayed or patients have poor adherence to insulin therapy *Shihchen Kuo and Chun-Ting Yang contributed equally to the work.
because of their fears about difficulty with injections, weight gain and hypoglycaemia. [6] [7] [8] Clinicians may have concerns about the safety profile and unfavourable clinical outcomes of insulin, and thus they choose to either maximize doses of three OADs or add another OAD as enhanced OAD therapy for patients with triple OAD therapy failure, regardless of the clear recommendation by the American Diabetes Association (ADA) 9 to initiate insulin therapy for these patients.
Current evidence from randomized controlled trials (RCTs) and longitudinal cohort studies on the cardiovascular outcomes of insulin therapy in patients with T2DM appears controversial. Favourable cardiovascular outcomes of intensive glycaemic control using sulphonylureas or insulin versus conventional therapy using diet control were documented in the 10-year follow-up UK Prospective Diabetes Study 10 ;
however, other RCTs either showed no significant benefits of insulin therapy on cardiovascular outcomes 11, 12 or revealed a link between insulin-based therapy and a greater number of non-fatal cardiovascular events. 13 Recently, two meta-analyses of RCTs suggested a neutral effect of insulin therapy on cardiovascular outcomes. 14, 15 These study findings should be interpreted with caution, however, because the studies included a limited number of cardiovascular events and shorter follow-up periods, the sulphonylureas used 10, 12 might also have had detrimental effects on cardiovascular disease (CVD), 16 and the study populations were specific to either patients at an early stage of diabetes 11 or those with existing CVD. 12, 13 Conversely, longitudinal cohort studies have shown an association between insulin therapy and increased risk of CVD and all-cause mortality in patients with T2DM, but the effects of insulin therapy were only assessed in patients at an early stage of the antidiabetic treatment course, with insulin being used as monotherapy, or as second-line or third-line antidiabetic treatment. [17] [18] [19] [20] [21] [22] [23] [24] Because T2DM is a progressive disease, most patients with T2DM
eventually require insulin therapy. Although it is quite common in realworld clinical practice for insulin therapy to be initiated at a later stage of an antidiabetic treatment course, the effects of insulin used as a fourth-line antidiabetic treatment in patients with T2DM who have failed to achieve glycaemic control on triple OAD therapy remain unknown. The aim of the present study, therefore, was first to investigate the risk of clinical outcomes associated with intensifying triple OAD therapy by initiating insulin (ie, in fourth-line insulin users) versus those of enhancing OAD therapy (ie, in potential insulin use candidates
[PICs]). Second, we sought to determine whether hypoglycaemia played a role in the relationship between insulin use and clinical outcomes.
Hypoglycaemia has been shown to contribute to the risk of developing CVD [25] [26] [27] ; thus, we hypothesized that the increased hypoglycaemia associated with insulin therapy might negatively impact the association between insulin therapy and clinical outcomes. Third, as basal insulin alone is recommended as the initial insulin regimen by the ADA, 9 we performed subgroup analyses to investigate whether the effects of insulin therapy differed according to insulin regimen.
| MATERIALS AND METHODS
This study was conducted with permission from the Institutional Review Board of National Cheng Kung University Hospital (B-EX-103-015).
| Data source
This was a retrospective cohort study using the Longitudinal Cohort 29 This dataset consists of longitudinal data (eg, disease diagnosis and prescription utilization records) from a random sample of 120 000 deidentified incident diabetes cases from each calendar year since 1999, which were tracked back to 1996 and followed up to 2013.
| Study population
Study patients extracted from the LHDB were newly diagnosed with
T2DM (International Classification of Diseases, ninth revision, Clinical
Modification [ICD-9-CM] codes: 250.x0, 250.x2, x = 0-9) for the period 1999 to 2010. We excluded those aged <18 years, and those diagnosed with type 1 diabetes or gestational diabetes. The study cohort selection process is detailed in Figure S1 .
| Exposure to antidiabetic drugs
The World Health Organization Anatomical Therapeutic Chemical Classification System was used to define antidiabetic drugs in the (Table S1 ). Maximal doses of OADs were defined according to information provided by drug product labels (Table S2 ).
| Definition of clinical outcomes
Primary outcomes included a composite outcome of non-fatal/fatal CVD (ie, myocardial infarction [MI], cerebrovascular disease, heart failure or ischaemic heart disease) and all-cause mortality. Secondary outcomes included individual CVD events, peripheral vascular disease (PVD) and hypoglycaemia. Using the ICD-9-CM codes, events of hospitalization for CVD and PVD were identified from the inpatient claims files, and events of hypoglycaemia were identified from the emergency department, inpatient and outpatient claims files (Table S3 ). The accuracy of disease diagnoses based on ICD-9-CM coding in the NHIRD has been validated in previous studies. [30] [31] [32] [33] [34] [35] 
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The incidence rate of study outcomes was calculated as the total number of events over the follow-up period divided by the number of person-years at risk. Cox proportional hazards models were used to compare risks of study outcomes between two propensity-scorematched cohorts. Hazard ratios (HRs) and two-tailed 95% confidence intervals (CIs) were computed. A two-tailed P value of <0.05 was considered statistically significant. Cumulative sums of martingale-based residuals were used to check the proportional hazard assumption in Cox models. 46 To consider the potential effect of hypoglycaemia on study outcomes, we adjusted for the presence of hypoglycaemia after the index date as a covariate in Cox models. Before adjustment for hypoglycaemia, we assessed the total effect of the fourth-line insulin therapy versus the enhanced OAD therapy on risks of CVDs and death, while after adjustment for hypoglycaemia, we assessed the remaining effect of the fourth-line insulin therapy after the partial effect of hypoglycaemia was considered. Akaike's information criterion (AIC) was used to evaluate the quality of model fit between models with and without adjustment for hypoglycaemia; a model with a lower AIC had a better fit.
Secondary analyses were conducted in a larger cohort incorporating the study cohort for primary analyses with those patients having prevalent diabetes-related complications (PDRCs) at baseline (1 year before index date). History of PRDCs was additionally considered in the PSM procedure. This analysis was conducted with the consideration that some patients with T2DM may have already had comorbid diseases before initiating insulin, and thus the secondary analysis results could be generalizable to the T2DM population in real-world clinical practice.
Sensitivity and subgroup analyses were performed using the study cohort for primary analyses. First, as-treated scenario analysis was conducted to account for over-estimation of the treatment effect from primary analyses, where non-adherence to medications was ignored. In addition to the censored definitions in primary analyses, patients were also censored when medication treatment patterns changed. Second, we redefined maximal doses of OADs according to clinicians' discretion/recommendations (Table S2) 3 | RESULTS
| Study cohort characteristics
We identified 3959 complication-free patients, with 1186 in the fourth-line insulin group and 2773 in the PIC group ( Figure S1 ). Table 1 shows patient characteristics by study group. After PSM, we included 1022 patients in each group for primary analyses; there was no statistical difference in patient characteristics between treatment groups. Table S5 shows the follow-up time for each study outcome in primary analyses. Table S6 shows that the fourth-line insulin group had a higher proportion of experiencing hypoglycaemia.
| Primary analyses

| Secondary analyses
In secondary analyses, we identified 2077 patients with T2DM with or without PDRCs in each group after PSM; there was no statistical difference in patient characteristics between groups (Table S4 ). 
| Sensitivity and subgroup analyses
Results of sensitivity analyses (Tables S8-S10) were consistent with those in primary analyses. In subgroup analyses, we selected two subgroups from the fourth-line insulin group, including: (a) 598 patients who initiated basal insulin alone vs. 598 propensity-scorematched PICs and (b) 517 patients who initiated LAIAs alone versus 517 propensity-score-matched PICs. The group of patients initiating LAIAs alone was a subgroup of patients initiating basal insulin alone.
As shown in Table 3 and Tables S11 and S12, the HRs for each study outcome were not statistically significant, except for hypoglycaemia Abbreviations: CVD, cardiovascular disease; HR, hazard ratio; MI, myocardial infarction; NA, not applicable; PIC, potential insulin use candidate; PVD, peripheral vascular disease. a Complication-free study cohort is defined as patients without diabetes-related complications (a) at 1 year before index date and (b) before stable use of fourth-line insulin in the fourth-line insulin users group and of enhanced OAD therapy in the PIC group. b CVD composite included myocardial infarction, cerebrovascular disease, heart failure, ischaemic heart disease, arrhythmia, arteriosclerotic CVD, aortic aneurysm, cardiogenic shock and cardiac arrest.
propensity-score-matched PIC group of patients; for example, the HR for the composite CVD outcome decreased from 1.37 to 1.00 and to 0.89.
| DISCUSSION
The ADA explicitly recommends insulin therapy for patients with T2DM who have failed to achieve glycaemic control on triple therapy. 9 In current clinical practice, however, a high proportion of such patients is still treated with either increasing doses of three OADs or by adding another OAD instead of initiating fourth-line insulin therapy. To our knowledge, this is the first large nationwide cohort study to evaluate the effects of initiating fourth-line insulin therapy in a real-world setting. First, we found that, in a T2DM cohort without PDRCs, initiating fourth-line insulin versus enhancing OAD therapy was not associated with increased risks of CVD, PVD or all-cause mortality. Second, in a T2DM population with or without PDRCs, fourth-line insulin was associated with increased risks of the composite outcome of CVD, heart failure, ischaemic heart disease, PVD and all-cause mortality. Third, fourth-line insulin was associated with a higher risk of hypoglycaemia than enhanced OAD therapy. Adjusting for hypoglycaemia reduced the risks of study outcomes and yielded lower AIC values of the models, suggesting that hypoglycaemia had a significant effect on the association between insulin therapy and increased CVD and all-cause mortality risks. Notably, among the T2DM population with or without PDRCs, adjusting for hypoglycaemia would neutralize excess risks of heart failure, PVD and all-cause mortality, which emphasizes the importance of awareness and prevention of hypoglycaemia among insulin-treated patients with T2DM.
Fourth, compared with the propensity-score-matched PIC group, initiation of fourth-line insulin therapy using LAIAs alone was associated with a lower risk of the composite CVD outcome, MI + cerebrovascular disease and PVD.
| Effects of the fourth-line insulin versus enhanced OAD therapy on clinical outcomes
The association of insulin therapy with incident CVD and mortality has been investigated previously, but evidence is lacking on the effects of initiating insulin as the fourth-line antidiabetic treatment in patients with T2DM. Previous longitudinal studies evaluated the effects of insulin when it was used as monotherapy, 17, 24 or secondline [17] [18] [19] [20] [21] 24 or third-line [22] [23] [24] treatment, and revealed a harmful effect of insulin therapy on CVD and all-cause mortality. Unlike previous studies, we found that intensification of triple OAD therapy by initiating fourth-line insulin versus enhancing OAD therapy was not associated with increased risks of the composite or individual outcomes of CVD, PVD or all-cause mortality in the complicationfree patients with T2DM, although it was associated with increased risks of some clinical outcomes among patients with or without PDRCs. Notably, one major concern in the previous studies is the bias attributable to confounding by indication because those studies compared insulin therapy with non-treatment, 24 or metformin 17, 24 or sulphonylureas 17 as monotherapy, or metformin + sulphonylureas 18, 20, 21 or metformin + dipeptidyl peptidase-4 (DPP-4) inibitors 19 as dual therapy. Indeed, characteristics of insulin users are typically different from patients without any treatment 24 or those with only one or two OADs. [17] [18] [19] 24 Unlike previous studies, we carefully identified a comparable group to the insulin-treated group and focused on evaluating the effects of fourth-line insulin therapy in patients with T2DM who failed to achieve glycaemic control on triple OAD therapy; in other words, all of our study patients had been candidates for insulin therapy. Moreover, we applied rigorous PSM approaches and identified baseline complication-free patients for primary analyses, which led to more comparable groups, minimized confounding by indication, and ensured causal inference in our study. a Complication-free study cohort is defined as patients without diabetes-related complications (a) at 1 year before index date and (b) before stable use of fourth-line insulin (or basal insulin alone or LAIAs alone) in the fourth-line insulin (or basal insulin or LAIA) users group and of enhanced OAD therapy in the PIC group. The group of patients initiating fourth-line basal insulin alone was a subgroup of patients initiating fourth-line insulin, and the group of patients initiating fourth-line LAIAs alone was a subgroup of patients initiating fourth-line basal insulin alone. b CVD composite included myocardial infarction, cerebrovascular diseases, heart failure, ischaemic heart disease, arrhythmia, arteriosclerotic cardiovascular disease, aortic aneurysm, cardiogenic shock and cardiac arrest. c HR could not be calculated because of the small number of events.
| Role of hypoglycaemia in relationship between insulin therapy and clinical outcomes
Hypoglycaemia is a major undesired effect of insulin therapy, and may play a role in a causal pathway between insulin therapy and risks of CVD and mortality. There is supporting evidence linking hypoglycaemia with increased risks of CVD and mortality in patients with T2DM or prediabetes, [47] [48] [49] [50] [51] but one study reported no significant relationship between severe/symptomatic hypoglycaemic events and CVD-specific/ all-cause mortality in patients with T2DM starting insulin therapy. 52 In the present study we found that the increased risks of clinical outcomes associated with insulin therapy became lower or even vanished after hypoglycaemia was adjusted for in the analyses, which provides the supporting evidence for the potential effect of hypoglycaemia on risks of CVD and mortality, and indicates the use of insulin per se may not be associated with increased risks of CVD and mortality ( Table 2 , Table S7 ). Considering all possible efforts will be made to minimize or avoid hypoglycaemia, such findings should reassure health professionals who may be reluctant to start insulin therapy because of the perception that it will have negative impacts on risks of CVD and mortality.
| Effects of initiating different types of insulin versus non-insulin therapy on clinical outcomes
Basal insulins, especially LAIAs, lead to a lower risk of hypoglycaemia than other types of insulin. 53, 54 Considering that hypoglycaemia may contribute to CVD risk, it would be worth further assessing the effects 
| Strengths and limitations
The present study has several strengths. First, it was based on a national representative cohort of patients with T2DM, with a longterm follow-up, and results could be applicable to patients who initiated insulin as a fourth-line antidiabetic treatment, which is a common prescription pattern of insulin use in real-world clinical practice, 4 is a highly recommended treatment strategy by the ADA for patients with triple OAD therapy failure, 9 and is suggested by Taiwan's NHI programme (because insulin is generally more expensive than OADs).
Second, rigorous statistical approaches were used to minimize common potential biases, including confounding by indication, selection bias and immortal-time bias, to ensure causal inference. Third, a series of sensitivity and subgroup analyses were conducted to ensure the robustness of study findings. Particularly, we further broke down different types of insulin to analyse the effects of using LAIAs, which may fill a research gap in previous studies.
Several limitations should also be acknowledged. First, we used PSM to control for patient characteristics between study groups, but, like any study using administrative claims data, the residual effects warranted to confirm our findings, especially the potential benefits of using LAIAs in T2DM on CVD and mortality.
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